AB Science
3, Avenue George V
Paris
75008
France
Tel: 33-(0)1-47200014
Fax: 33-(0)1-47202411
Website: http://www.ab-science.com/
Email: contact@ab-science.com
121 articles about AB Science
-
AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease
3/13/2024
AB Science SA announced the publication of new preclinical results for masitinib in neurodegenerative diseases.
-
AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development
3/7/2024
AB Science SA is providing a summary of the live webcast held on March 4, 2024, giving an update on AB Science development.
-
AB Science announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated coverage of the Company
3/6/2024
AB Science SA announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated the coverage of the Company.
-
AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET
2/29/2024
AB Science SA will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET.
-
AB Science announces that Health Canada has issued a Notice of Non-Compliance-Withdrawal (NON/w) for masitinib in ALS
2/26/2024
AB Science SA (Euronext - FR0010557264 - AB) today announces that Health Canada has issued a Notice of Non-Compliance-Withdrawal (NON/w) regarding its New Drug Submission (NDS) for masitinib in the treatment of amyotrophic lateral sclerosis (ALS).
-
AB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines Agency
1/26/2024
AB Science SA (Euronext – FR0010557264 – AB) announced that the Committee for Medicinal Products for Human Use (CHMP) has proposed that AB Science submit a written response to the List of Outstanding Issues at D195 of the procedure, instead of addressing these issues through the Oral Explanation.
-
AB Science receives notice of allowance for European patent covering masitinib until 2036 in the treatment of mastocytosis
1/15/2024
AB Science SA (Euronext - FR0010557264 - AB) today announced that the European Patent Office has issued a Notice of Allowance for a patent relating to methods of treating severe systemic mastocytosis (i.e. a medical use patent) with its lead compound masitinib, based on findings from study AB06006 [1].
-
AB Science will host a live webcast on Thursday November 30, 2023, from 3pm to 4pm CET, to present the masitinib development program in sickle cell disease
11/28/2023
AB Science SA (Euronext – FR0010557264 – AB) will host a live webcast on Thursday November 30, 2023, from 3pm to 4pm CET, to present the masitinib development program in sickle cell disease.
-
AB Science: The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”
11/27/2023
AB Science SA announces that a new clinical development program for masitinib in sickle cell disease is among the 19 winning projects to be funded under the sixth call for "Hospital-University Research in Health" projects, which is part of the Future Investments Program.
-
AB Science today reports its revenues for the first half of 2023 and provides an update on its activities
9/29/2023
AB Science wants to focus the majority of our clinical resources on the development of rare diseases with masitinib, on the development of the microtubule platform with AB8939 and future molecules of the same family due to the very encouraging first results.
-
AB Science provides an update on the EMA timetable for examination of the masitinib marketing authorization application in ALS
9/18/2023
AB Science SA (Euronext – FR0010557264 – AB) today provided an update on the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) timetable for examination of the masitinib marketing authorization application in amyotrophic lateral sclerosis (ALS).
-
AB Science receives Notice of Allowance for European patent covering masitinib in the treatment of metastatic castrate refractory prostate cancer (mCRPC)
6/26/2023
AB Science SA (Euronext - FR0010557264 - AB) today announced that the European Patent Office has issued a Notice of Allowance for a patent relating to methods of treating (mCRPC) with its lead compound masitinib, based on findings from study AB12003.
-
AB Science announces issuance of a Canadian patent for masitinib in the treatment of ALS with protection until 2037
6/1/2023
AB Science SA (Euronext - FR0010557264 - AB) today announced that the patent office of Canada has issued a Notice of Allowance (NOA) for a patent relating to methods of treating amyotrophic lateral sclerosis (ALS) with its lead compound masitinib (CA 3018635).
-
AB Science summarizes key messages from its participation to a panel discussion at the 2023 ALS Drug Development Summit
5/17/2023
AB Science SA (Euronext – FR0010557264 – AB) today summarizes the key messages delivered to an audience of key opinion leaders and decision-makers in the field of ALS research and healthcare policy, during an Panel Discussion at the ALS Drug Development Summit in Boston, USA (May 16-18, 2023).
-
AB Science announces that Health Canada has resumed its review of the New Drug Submission for masitinib in amyotrophic lateral sclerosis, following issuance of a screening acceptance letter
5/9/2023
AB Science SA (Euronext - FR0010557264 - AB) today announces that Health Canada has issued a screening acceptance letter for the application of masitinib in the treatment of amyotrophic lateral sclerosis (ALS).
-
AB Science reports its revenues for the year 2022 and provides an update on its activities
4/28/2023
AB Science SA reports its revenues for the year 2022 and provides an update on its activities.
-
AB Science - Summary of the presentation on masitinib in ALS delivered at 2023 AAN Annual Meeting
4/27/2023
AB Science SA summarizes the presentation that was made on masitinib in amyotrophic lateral sclerosis at the American Academy of Neurology 2023 Annual Meeting in Boston, USA.
-
AB Science announces masitinib patent granted in Japan for the treatment of amyotrophic lateral sclerosis, strengthening the Company’s intellectual property position until 2037
4/18/2023
AB Science SA (Euronext - FR0010557264 - AB) today announced that the patent office of Japan has issued a Notice of Allowance (NOA) for a patent relating to methods of treating amyotrophic lateral sclerosis (ALS) with its lead compound masitinib (JP 2022037132A).
-
AB Science: Results of masitinib in ALS selected for a scientific platform presentation at the AAN 2023, including long-term survival analysis and a new analysis of patient population with no complete loss of function at baseline
4/12/2023
AB Science SA announced that Professor Albert Ludolph, MD, PhD, will deliver a presentation on masitinib in amyotrophic lateral sclerosis to an audience of key opinion leaders in the field of ALS healthcare, at the up-coming American Academy of Neurology 2023 Annual Meeting in Boston, USA.
-
AB Science announces that it has submitted its response to the day 120 questions in the EMA regulatory review of masitinib in amyotrophic lateral sclerosis and clarifies the new timeline for responding to Health Canada
4/4/2023
AB Science S.A. provides an update on the schedule for the evaluation by the Committee for Medicinal Products for Human Use of the European Medicines Agency and by Health Canada of its applications for conditional approval of masitinib in the treatment of amyotrophic lateral sclerosis.